Current Infectious Disease Reports

, Volume 6, Issue 2, pp 141–148 | Cite as

Adolescent sexually transmitted diseases: Recent developments

  • Diane R. Blake
Article

Abstract

Adolescents and young adults continue to have the highest rates of sexually transmitted diseases. New chlamydia and gonorrhea diagnostic tests are being used in innovative ways to increase the number of infections that are detected. Nevertheless, challenges such as gonorrhea resistance and partner notification and treatment continue to hinder efforts to reduce the prevalence of these two bacterial infections. Although recent surveillance data suggest a decreasing trend of herpes simplex virus 2 (HSV-2) incidence among adolescents and young adults, the incidence of sexually transmitted human papillomavirus (HPV) in adolescent and young adult females remains high. Progress has been made toward the development of vaccines that may become available in the future to prevent infection with and sequelae from HSV-2 and HPV.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Alexander LL, Cates JR, Herndon N, Ratcliffe JM: Sexually transmitted diseases in America: how many cases and at what cost? Menlo Park, CA: Kaiser Family Foundation; 1998.Google Scholar
  2. 2.
    Centers for Disease Control and Prevention: Sexually Transmitted Diseases Surveillance, 2002. Atlanta, GA: US Department of Health and Human Services; 2003.Google Scholar
  3. 3.
    Centers for Disease Control and Prevention: Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections--2002. MMWR Morb Mortal Wkly Rep 2002, 51:9–14. This report emphasizes chlamydia screening. These guidelines consider tests from an economic perspective and expand the previous guidelines to address detection of N. gonorrhoeae and C. trachomatis infections. This report also addresses the need for additional testing after a positive screening test result to improve the specificity of a final diagnosis.Google Scholar
  4. 4.
    United States Preventive Services Task Force: Screening: chlamydial infection. http://www.ahcpr.gov/clinic/uspstf/ uspschlm.htm. Accessed September 25, 2003.Google Scholar
  5. 5.
    Burstein GR, Zenilman JM: Non-gonococcal urethritis--a new paradigm. Clin Infect Dis 1999, 28(Suppl 1):S66-S73.PubMedCrossRefGoogle Scholar
  6. 6.
    Burstein GR, Zenilman JM, Gaydos CA, et al.: Predictors of repeat Chlamydia trachomatis infections diagnosed by DNA amplification testing among inner city females. Sex Transm Infect 2001, 77:26–32.PubMedCrossRefGoogle Scholar
  7. 7.
    Corey L, Wald A: Genital herpes. In Sexually Transmitted Diseases, edn 3. Edited by Holmes KK, Sparling PF, Mardh PA, et al. New York: McGraw-Hill; 1999:285–312.Google Scholar
  8. 8.
    Lafferty WE, Downey L, Celum C, Wald A: Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention. J Infect Dis 2000, 181:1454–1457.PubMedCrossRefGoogle Scholar
  9. 9.
    Armstrong GL, Schillinger J, Markowitz L, et al.: Incidence of herpes simplex virus type 2 infection in the United States. Am J Epidemiol 2001, 153:912–920.PubMedCrossRefGoogle Scholar
  10. 10.
    Xu F, McQuillan GM, Kottiri BJ, et al.: National seroprevalence and trends in herpes simplex virus type 1 and type 2 infection in the United States, 1988–2000. In Programs and abstracts in the 15th Biennial Congress of the International Society for Sexually Transmitted Diseases 2003. Ottawa: International Society for Sexually Transmitted Diseases; 2003:58–59.Google Scholar
  11. 11.
    Wald A, Zeh J, Selke S, et al.: Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Eng J Med 2000, 342:844–850.CrossRefGoogle Scholar
  12. 12.
    De Villiers EM: Taxonomic classification of papillomaviruses. Papillomavirus Rep 2001, 12:57–63.Google Scholar
  13. 13.
    Munoz N, Bosch FX, de Sanjose S, et al.: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Eng J Med 2003, 348:518–527.CrossRefGoogle Scholar
  14. 14.
    Moscicki AB, Hills N, Shiboski S, et al.: Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001, 285:2995–3002.PubMedCrossRefGoogle Scholar
  15. 15.
    Moscicki AB, Shiboski S, Broering J, et al.: The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998, 132:277–284.PubMedCrossRefGoogle Scholar
  16. 16.
    Nsuami M, Migel E, Brooks BN, et al.: Screening for sexually transmitted diseases during preparticipaton sports examination of high school adolescents. J Adolesc Health 2003, 32:336–339.PubMedCrossRefGoogle Scholar
  17. 17.
    Kettle H, Cay S, Brown A, Glasier A: Screening for Chlamydia trachomatis infection is indicated for women under 30 using emergency contraception. Contraception 2002, 66:251–253.PubMedCrossRefGoogle Scholar
  18. 18.
    Mertz KJ, Voigt RA, Hutchins K, et al.: Findings from STD screening of adolescents and adults entering corrections facilities. Sex Transm Dis 2002, 29:834–839.PubMedCrossRefGoogle Scholar
  19. 19.
    Van Leeuwen JM, Rietmeijer CA, LeRoux T, et al.: Reaching homeless youths for Chlamydia trachomatis and Neisseria gonorrhoeae screening in Denver, Colorado. Sex Transm Infect 2002, 78:357–359.PubMedCrossRefGoogle Scholar
  20. 20.
    Kahn RH, Moseley KE, Thilges JN, et al.: Community-based screening and treatment for STDs: results from a mobile clinic initiative. Sex Transm Dis 2003, 30:654–658.PubMedCrossRefGoogle Scholar
  21. 21.
    Stamm WE: Chlamydia trachomatis infections in the adult. In Sexually Transmitted Diseases, edn 3. Edited by Holmes KK, Sparling PF, Mardh PA, et al. New York: McGraw-Hill; 1999:407–422.Google Scholar
  22. 23.
    Wang LY, Burstein GR, Cohen DA: An economic evaluation of a school-based sexually transmitted disease screening program. Sex Transm Dis 2002, 29:737–745.PubMedCrossRefGoogle Scholar
  23. 24.
    Ginocchio RH, Veenstra DL, Connell FA, Marrazzo JM: The clinical and economic consequences of screening young men for genital chlamydial infection. Sex Transm Dis 2003, 30:99–106.PubMedCrossRefGoogle Scholar
  24. 25.
    Mrus JM, Biro F, Huang B, Tsevat J: Evaluating adolescents in juvenile detention facilities for urogenital chlamydial infection. Arch Pediatr Adolesc Med 2003, 157:696–702.PubMedCrossRefGoogle Scholar
  25. 26.
    Blake DR, Gaydos CA, Quinn TC: Cost-effectiveness analysis of screening adolescent males for chlamydia on admission to detention. Sex Transm Dis 2004, 31:85–95.PubMedCrossRefGoogle Scholar
  26. 27.
    Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 2002, 51:1–78. Included in these guidelines are expanded sections on the diagnosis of genital herpes (including type-specific serologic tests) and expanded regimens for the treatment of urethral meatal warts. In addition, these guidelines emphasize education and counseling for persons infected with HPV and present information regarding the emergence of quinolone-resistant N. gonorrhoeae and implications for treatment.Google Scholar
  27. 28.
    Ashley RL: Sorting out the new HSV type specific antibody tests. Sex Transm Infect 2001, 77:232–237.PubMedCrossRefGoogle Scholar
  28. 29.
    Ribes JA, Smith A, Hayes M, et al.: Comparative performance of herpes simplex virus type 1-specific serologic assays from MRL and Meridian diagnostics. J Clin Microbiol 2002, 40:1071–1072.PubMedCrossRefGoogle Scholar
  29. 30.
    Ribes JA, Hayes M, Smith A, et al.: Comparative performance of herpes simplex virus type 2-specific serologic assays from Meridian diagnostics and MRL diagnostics. J Clin Microbiol 2001, 39:3740–3742.PubMedCrossRefGoogle Scholar
  30. 31.
    Ashley RL, Wald A, Eagleton M: Premarket evaluation of the POCkit HSV-2 type-specific serologic test in culturedocumented cases of genital herpes simplex virus type 2. Sex Transm Dis 2000, 27:266–269.PubMedCrossRefGoogle Scholar
  31. 32.
    Prince HE, Ernst CE, Hogrefe WR: Evaluation of an enzyme immunoassay system for measuring herpes simplex virus (HSV) type 1-specific and HSV type 2-specific IgG antibodies. J Clin Lab Anal 2000, 14:13–16.PubMedCrossRefGoogle Scholar
  32. 33.
    Hubbard RA: Human papillomavirus testing methods. Arch Pathol Lab Med 2003, 127:940–945.PubMedGoogle Scholar
  33. 34.
    Schiffman M, Solomon D: Findings to date from the ASCUS-LSIL triage study (ALTS). Arch Pathol Lab Med 2003, 127:946–949.PubMedGoogle Scholar
  34. 35.
    Centers for Disease Control and Prevention: Sexually Transmitted Diseases Surveillance Report Supplement: Gonococcal Isolate Surveillance Project (GISP) Annual Report--2001. Atlanta, GA: US Department of Health and Human Services; 2002.Google Scholar
  35. 36.
    Burstein GR, Berman SM, Blumer JL, Moran JS: Ciprofloxacin for the treatment of uncomplicated gonorrhea infection in adolescents: does benefit outweigh risk? Clin Infect Dis 2002, 35:S191-S199.PubMedCrossRefGoogle Scholar
  36. 37.
    Increases in fluoroquinolone-resistant Neisseria gonorrhoeae--Hawaii and California, 2001. MMWR Morb Mortal Wkly Rep 2002, 51:1041-1044.Google Scholar
  37. 38.
    Cipro (ciprofloxacin hydrochloride) tablets and Cipro (ciprofloxacin) oral suspension. In Physicians’ Desk Reference, edn 57. Montvale, NJ: Thompson PDR; 2003:875-885.Google Scholar
  38. 39.
    Centers for Disease Control and Prevention: Notice to readers: discontinuation of cefixime tablets--United States. MMWR Morb Mortal Wkly Rep 2002, 51:1052.Google Scholar
  39. 40.
    Centers for Disease Control and Prevention: Oral alternatives to cefixime for the treatment of uncomplicated Neisseria gonorrhoeae urogenital infections. http://www.cdc.gov/STD/ treatment/Cefixime.htm. Accessed October 12, 2003. This article provides useful suggestions for treatment of uncomplicated N. gonorrhoeae genital infections if cefixime is unavailable.Google Scholar
  40. 41.
    Steiner KC, Davila V, Kent CK, et al.: Field-delivered therapy increases treatment for chlamydia and gonorrhea. Am J Public Health 2003, 93:882–884.PubMedCrossRefGoogle Scholar
  41. 42.
    Schillinger JA, Kissinger P, Calvet H, et al.: Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women: a randomized controlled trial. Sex Transm Dis 2003, 30:49–56.PubMedCrossRefGoogle Scholar
  42. 43.
    Saslow D, Runowica CD, Solomon D, et al.: American Cancer Society guidelines for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002, 52:342–362.PubMedCrossRefGoogle Scholar
  43. 44.
    Stanberry L, Spruance SL, Cunningham AL, et al.: Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Eng J Med 2002, 347:1652–1661.CrossRefGoogle Scholar
  44. 45.
    Wald A, Corey L, Cone R, et al.: Frequent genital herpes simplex virus 2 shedding in immunocompetent women: effect of acyclovir treatment. J Clin Invest 1997, 99:1092–1097.PubMedCrossRefGoogle Scholar
  45. 46.
    Corey L, Wald A, Parel R, et al.: Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004, 350:11–20.PubMedCrossRefGoogle Scholar
  46. 47.
    Koutsky LA, Ault KA, Wheeler CM, et al.: A controlled trial of a human papillomavirus type 16 vaccine. N Eng J Med 2002, 347:1645–1651.CrossRefGoogle Scholar
  47. 48.
    Blake DR, Kearney MH, Oakes JM, et al.: Improving participation in Chlamydia screening programs: perspectives of high risk youth. Arch Pediatr Adolesc Med 2003, 157:523–529.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Diane R. Blake
    • 1
  1. 1.Department of PediatricsUniversity of Massachusetts Medical SchoolWorcesterUSA

Personalised recommendations